TECH Stock Overview
Develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bio-Techne Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$82.98 |
| 52 Week High | US$89.91 |
| 52 Week Low | US$51.79 |
| Beta | 1.23 |
| 1 Month Change | 32.13% |
| 3 Month Change | 15.64% |
| 1 Year Change | 1.53% |
| 3 Year Change | -20.26% |
| 5 Year Change | 71.31% |
| Change since IPO | 12,852.98% |
Recent News & Updates
Recent updates
Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Bio-Teche announces transition plan for CEO Kummeth
Aug 04Bio-Techne: Resiliency Comes At A Large Premium
Jul 29Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer
Jul 06Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?
Jun 22Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?
Jun 09Shareholder Returns
| TECH | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.6% | -1.3% | -0.2% |
| 1Y | 1.5% | 10.0% | 28.2% |
Return vs Industry: TECH underperformed the US Life Sciences industry which returned 8% over the past year.
Return vs Market: TECH underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| TECH volatility | |
|---|---|
| TECH Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TECH's share price has been volatile over the past 3 months.
Volatility Over Time: TECH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 3,050 | Kim Kelderman | www.bio-techne.com |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Bio-Techne Corporation Fundamentals Summary
| TECH fundamental statistics | |
|---|---|
| Market cap | US$13.03b |
| Earnings (TTM) | US$202.96m |
| Revenue (TTM) | US$1.15b |
64.4x
P/E Ratio11.3x
P/S RatioIs TECH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECH income statement (TTM) | |
|---|---|
| Revenue | US$1.15b |
| Cost of Revenue | US$380.84m |
| Gross Profit | US$773.45m |
| Other Expenses | US$570.49m |
| Earnings | US$202.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.29 |
| Gross Margin | 67.01% |
| Net Profit Margin | 17.58% |
| Debt/Equity Ratio | 19.3% |
How did TECH perform over the long term?
See historical performance and comparison